SLC7A11 and primary effusion lymphoma: More importantly, we demonstrated that an xCT selective inhibitor, Sulfasalazine (SASP), effectively prevents PEL tumor progression in an immune-deficient xenograft model [5], which suggests that xCT may represent a promising target for AIDS-related lymphomas.